Newsletter |
ENJOY YOUR
FLIGHT!
|
|
A clinical trial is like an air journey. You first prepare a flight plan (the trial protocol) which must be approved by air traffic control (the regulators). Before taking off (enrolling the first patient), the captain (the lead collaborator at each site) must ensure that all the relevant documents have been seen and approved (ethics approvals). It takes a huge amount of energy (effort) to get a plane (a trial) off the ground but eventually it reaches the correct cruising altitude (monthly recruitment rate). The CRASH-2 trial is now recruiting around 450 patients per month and is getting close to its cruising altitude of 550 patients per month. We have covered a lot of ground (11,000 patients recruited) and hope to arrive at our destination (20,000 patients recruited) on schedule (December 2009). Just like air travel, safety is our primary concern. In the CRASH-2 trial patient safety is inspected regularly by an expert independent data monitoring committee. This newsletter shows their latest report. You will be reassured that there are no safety concerns and that the committee strongly encourages us to keep recruiting so that we reach our destination on time. The data monitoring committee checks the accumulating trial data and to do its job properly it is vital that the trial data are accurate and complete. In this newsletter the trial Data Manager Lin Barnetson explains what data checking involves and why obtaining complete data on every randomised patient is essential. At this stage it is tempting to say "so sit back and enjoy your flight" but this is a newsletter for captains (collaborators) rather than passengers (patients)! The message for captains is "full throttle, safety is the primary concern and keep in touch with the ground staff"! On target
recruitment keeps us airborne good quality data and completeness
of follow-up ensures a safe and happy landing. |
The DATA MONITORING AND ETHICS COMMITTEE recommends that the trial continue unchanged and encourages the investigators to increase recruitment rates. |
MONITORING THE ACCURACY AND QUALITY OF THE CRASH-2 TRIAL DATA |
|
WHY IS THIS IMPORTANT? The integrity of the CRASH-2 Trial data must be verified to ensure the results of the trial are valid and the safety of future patients is protected. |
|
HOW DO WE MONITOR DATA QUALITY? INDEPENDENT OVERVIEW In CRASH-2 we have an independent Data Monitoring and Ethics Committee (DMEC) who review our unblinded data on a regular basis. This review was last carried out on 2 June 2008 on 9,210 patients see the latest feedback from DMEC in this newsletter. In addition to reviewing the unblinded data to ensure the trial remains safe for patients, the DMEC also look at our rate of recruitment, how we ensure the security of the blinding of the trial and the quality of data we receive. The quality review includes the number of protocol violators, the number of packs used out of sequence and percentage of missing data. We also provide the DMEC with information on our quality assurance procedures. |
|
TCC MONITORING PROCEDURE The following are some of the procedures we carry out here at the TCC. Checks are made within each collaborating centre and across the trial as a whole. Daily computerised validity and consistency checks on both entry and outcome data. These can give rise to queries which we resolve directly with the investigators at each site. The data are also subjected to monthly statistical checks for irregularities (International Society for Clinical Biostatistics Subcommittee on Fraud, Statist Med 1999;18:3435-51) such as:
By comparing means, standard deviations and coefficient of variance, sites showing any of the anomalies listed above are identified. These checks are only carried out on sites with an adequate sample size for analysis. Figure 1 shows the results for systolic BP where 3 sites fall out with the normal distribution. All measures are subjected to regular checks for relative frequencies and these are compared across the trial. Figure 2 shows the output for one of the standard checks carried out to examine the primary outcome (mortality) for the trial. The figure indicates the number of sites with mortality rates that fall below or are above the expected range. Validation checks
are also carried out between baseline measures and outcome event rates,
e.g. severity of capillary refill time v mortality. Site visits and source data verification of between 5-100% is also routinely carried out depending on specific rates of recruitment. This involves a member of the TCC staff / National Co-ordinator visiting your hospital. Monitoring visits should also be regarded as an opportunity to ask questions and consolidate knowledge of the trial processes and progress. Many of you have experienced our audits and we hope you have found them useful. |
ARE
WE RECRUITING THE CORRECT PATIENTS?
|
ARE
WE ACHIEVING THE EXPECTED OUTCOME EVENTS RATE?
|
Many congratulations to all the teams listed below who will receive a prize for being among the top 50 recruiters during the incentive period of 18 April 11 July 2008, leading up to 10,000 randomised patients! |
|
COLOMBIA: Fundacion Clinica Valle del Lili; Hospital San Felix ESE; Hospital Universitario Del Caribe; Hospital Universitario San Jose De Popayan; Hospital Universitario San Vicente de Paul CUBA: Hospital Abel Santamaria Cuadrado; Hospital Clínico-Quirúrgico Docente "Saturnino Lora; Hospital Provincial Docente "Manuel Ascunce Domenech ECUADOR: Hospital Luis Vernaza EGYPT: Mataria Teaching Hospital; Suez Canal University GEORGIA: Tbilisi City Hospital #1; Tbilisi First Hospital, University Clinic, Neurosurgery Center; Tbilisi State Medical University, ER Department; Tbilisi State University Clinical Hospital 'I Javakhishvili INDIA: Aditya Neuroscience Centre; Apollo Health City; Bhattacharya Orthopaedic and Related Research Centre; Calicut Medical College Hospital; Care Hospital; Christian Medical College Hospital Vellore; Government Medical College and Associated Hospitals Jammu; Government Rajaji Hospital; Goyal Hospital Jalna; KLE Hospital & Medical Research Centre; Krishnamai Medical & Research Foundation's NIKOP Hospital; LTM Medical College and General Hospital; Medical Trust Hospital Kochi; MKCG Medical College; NKP Salve Institute of Medical Sciences and Lata Mangeshkar Hospital; North Bengal Neuro Research Centre; Sanjeevani Hospital; Sanjivani Hospital; Sheth VS General Hospital & NHL Municipal College INDONESIA: Saiful Anwar General Hospital; Sanglah General Hospital MALAYSIA: Hospital University Science Malaysia MEXICO: Hospital General Regional 25; Hospital Gustavo Rovirosa NIGERIA: Baptist Medical Centre, National Hospital Abuja; National Orthopaedic Hospital Enugu; University of Benin Teaching Hospital; University of Uyo Teaching Hospital PERU: Hospital Nacional Hipólito Unanue; Hospital Regional Docente de Trujillo SRI LANKA: National Hospital of Sri Lanka THAILAND: Khon Kaen Regional Hospital; Pattani Hospital; Suratthani Hospital |
|
Pankaj Patels team at Sheth VS General Hospital, India, have found a good way to spend the prize money! |
high achievers CONGRATULATIONS! |
|
100
50
|
NEW ETHICS APPROVALS | |
CAMEROON
ECUADOR
GHANA
|
|
INDIA
KENYA
NIGERIA
THAILAND
|
|
NEW RANDOMISERS | |
|
CRASH AROUND THE WORLD | |
Team from Hospital Regional Docente de Trujillo in Peru, with PI Jose Caballero Alvarado |
|
Bhumibol Adulyadej Hospital team in Thailand, with PI Kamol Wattanakrai |
|
Christian Medical College, Vellore, India, with PI Suresh David |
cochrane corner | |
The
Cochrane Injuries Group registers titles for reviews related to the prevention,
treatment and rehabilitation of traumatic injury. The reviews are published
on the Cochrane Library www3.interscience.wiley.com.
Most countries have a subscription to the Cochrane Library. If you are
unable to access the reviews feel free to contact the review group co-ordinator
at Emma.Sydenham@Lshtm.ac.uk,
also if you have an idea for a new title. Check out our new website for
information and to get involved: www.injuries.cochrane.org
|